Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition
Cellular Oncology · 2026
DOI: 10.1007/s13402-025-01154-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2026. Verfasst von Vera E van der Noord und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, 2300 RA, The …. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 9, Triple Negative Breast Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Dutch Cancer Society.
Abstract (Originalsprache)
Purpose
CDK9, in complex with cyclin T1 or T2, is essential for mRNA transcription by enabling paused RNA polymerase II to proceed into elongation. Increasing evidence highlights CDK9’s involvement in transcriptional addiction in cancer. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype for which effective targeted therapies remain limited. Here, we aimed to define the therapeutic potential of novel CDK9 inhibitors in TNBC.
Methods
We explored the efficacy and mechanism of action of novel CDK9 inhibitors, alone or in combination with EGFR inhibitors, using TNBC cell lines and in vivo xenograft models.
Results
Targeting CDK9 significantly impaired proliferation and induced apoptosis in multiple TNBC cell lines. Transcriptomic analyses revealed that CDK9 inhibitors induced downregulation of genes involved in transcription, cell cycle progression, and oncogenic signalling pathways, including TGF-β and Wnt/β-catenin signalling. Combined CDK9 and EGFR inhibition disrupted transcriptional programs, enhanced TNBC cell death in vitro, and acted synergistically to reduce tumour growth in PDX and Hs578T xenograft models, although this combination was also associated with increased toxicity.
Conclusion
Our results position CDK9 as a promising therapeutic target in TNBC, either alone or in combination with EGFR inhibition, provided that side effects associated with this combination treatment can be controlled.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, 2300 RA, The Netherlands. v.e.van.der.noord@lacdr.leidenuniv.nl.
- Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, 2300 RA, The Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Cancer Genomic Netherlands, Erasmus University Medical Center, Rotterdam, 3000 CA, The Netherlands.
- Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia.
- Preclinical Intervention Unit, Netherlands Cancer Institute, Mouse Clinic for Cancer and Aging (MCCA), Amsterdam, 1066 CX, The Netherlands.
- Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, 2300 RA, The Netherlands. b.water@lacdr.leidenuniv.nl.
Förderung
- European Research Council
- Dutch Cancer Society
Zitieren
APA
van der Noord, V. E., McLaughlin, R. P., Karuntu, J. S., He, J., Timmermans, A. M., Basnet, S. K. C., Long, Y., Diab, S. A. H., Tadesse, S., Proost, N., van Gerwen, B., Siteur, B., van de Ven, M., Pont, C., Le Dévédec, S. E., Martens, J. W. M., Wang, S., Zhang, Y., & van de Water, B. (2026). Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition. Cellular Oncology. https://doi.org/10.1007/s13402-025-01154-6
Vancouver
van der Noord VE, McLaughlin RP, Karuntu JS, He J, Timmermans AM, Basnet SKC, et al. Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition. Cellular Oncology. 2026. doi:10.1007/s13402-025-01154-6
BibTeX
@article{vanderNoord2026,
author = {van der Noord, Vera E and McLaughlin, Ronan P and Karuntu, Jessica S and He, Jichao and Timmermans, A Mieke and Basnet, Sunita K C and Long, Yi and Diab, Sarah Al Haj and Tadesse, Solomon and Proost, Natalie and van Gerwen, Bastiaan and Siteur, Bjørn and van de Ven, Marieke and Pont, Chantal and Le Dévédec, Sylvia E and Martens, John W M and Wang, Shudong and Zhang, Yinghui and van de Water, Bob},
title = {Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition},
journal = {Cellular Oncology},
year = {2026},
doi = {10.1007/s13402-025-01154-6}
}
EUVIMED